Impact of Fusobacterium nucleatum in the treatment of cancer, including radiotherapy and its future potential in esophageal cancer Authors: Manato Ohsawa, Hiromi Nishi, Manabu Emi, Toru Yoshikawa, Yoichi Hamai, Yuta Ibuki, Tomoaki Kurokawa, Ryosuke Hirohata, Nao Kitasaki, Miki Kawada-Matsuo, Hitoshi Komatsuzawa, Hiroyuki Kawaguchi, Morihito Okada Published: 2024 ABSTRACT AbstractDespite advances in multimodality therapy, including surgery, chemotherapy, radiation therapy and chemoradiation, the fatality rate for esophageal cancer remains high. Specifically, Fusobacterium nucleatum, due to its aggregation capacity, has shown a tendency to form biofilms. The biofilm-forming capabilities of microbial communities are of utmost importance in the context of cancer treatment, as they have been shown to drive significant losses in the efficaciousness of various cancer treatments. Therefore, elucidating the dynamics of F. nucleatum will be important for the development of effective treatments for esophageal cancer. Therefore, this review summarizes the current knowledge of F. nucleatum, its involvement in cancer and its impact on chemotherapy and radiation therapy. In conclusion, further research on the role of F. nucleatum is essential for the continued advancement of the treatment of esophageal cancer and patient care.Keywords: microbiome, F. nucleatum, esophageal cancer, chemotherapy, radiotherapy INTRODUCTION Esophageal cancer is the seventh most common cancer and the sixth most common cause of cancer-related deaths worldwide [1]. Squamous cell carcinoma is the predominant type of esophageal cancer, accounting for ~90% of all cases globally [1, 2]. Despite advances in multimodal therapies such as surgery, chemotherapy, radiotherapy and chemoradiotherapy, esophageal cancer remains a highly lethal malignancy, with a 5-year overall survival (OS) rate of 15–20% [3, 4]. Trimodal neoadjuvant chemotherapy, radiotherapy and surgery are required to control locally advanced esophageal cancer and improve patient survival [5, 6]. Prognosis after trimodal therapy is related to the response of patients to neoadjuvant therapy [7, 8]. In Japan, the standard therapy for locally advanced esophageal cancer is docetaxel, cisplatin and 5-fluorouracil (i.e. neoadjuvant chemotherapy), followed by surgery [9]. Moreover, nivolumab is recommended as adjuvant therapy for patients who failed to achieve a pathologic complete response on postoperative pathology [10]. The use of radiation therapy in esophageal cancer treatment widely varies; for example, neoadjuvant chemoradiotherapy, radical chemoradiotherapy and radiation therapy alone. As mentioned earlier, surgery after neoadjuvant chemotherapy has not only become the standard treatment in Japan, but also worldwide. Specifically, neoadjuvant chemoradiotherapy is generally used as a multidisciplinary treatment for resectable, locally advanced esophageal cancer. Radical chemoradiotherapy is also utilized for patients with poor operative tolerance, those who wish to preserve the esophagus, those who wish to preserve the larynx in cervical esophageal cancer and those who are unresectable owing to invasion of surrounding organs. Radiation therapy alone is an option for patients who are unable to undergo endoscopic therapy or chemoradiotherapy. In the treatment of recurrent disease, chemoradiotherapy or radiation therapy alone is used for localized recurrence, and palliative irradiation for pain and bleeding is performed. In neoadjuvant chemoradiotherapy, a pathological complete response rate of 27–29% is reported for treatment efficacy, which is higher than that for neoadjuvant chemotherapy [5, 11]. However, some patients develop resistance to chemoradiotherapy, particularly radioresistance, which remains an important obstacle to improving the efficacy of chemoradiotherapy. Additionally, the reduction of radiation-related toxicity is one of the primary challenges in the treatment of esophageal cancer. The mechanisms of radio resistance mainly involve the transformation of normal stem cells into cancer stem cells through genetic mutations and aberrant expression; enhanced repair of exogenous deoxyribonucleic acid (DNA) damage such as mismatches, base isomerization and DNA strand breaks; inhibition of the production of reactive oxygen species that cause oxidative protein damage; cancer cell metastasis and epithelial–mesenchymal transition that promote proliferation and mitochondrial autophagy-mediated resolution of dysfunction and regulation of oxidative stress [12]. Microbiome research has made rapid progress in recent years. Over 100 trillion bacteria inhabit the human body, forming microbiota in individual organs. The human gut microbiota plays crucial roles in host metabolism, bolstering the immune system, maintaining the gut mucosal barrier and defense against pathogens [13–15]. In recent years, the gut microbiota has received increasing attention in the study of various malignancies, with evidence suggesting that it is involved in the development and progression of gastrointestinal cancers through the regulation of gut inflammation and tumor-related signaling pathways [16–19]. Recent studies suggest that gut microbiota composition is associated with the therapeutic efficacy of immunotherapy and chemotherapy [20, 21]. Similarly, the oral microbiota plays a significant role in periodontal disease, which is associated with various systemic conditions, including atrial fibrosis, stroke, oral human papillomavirus16 infection—a known risk factor for oral squamous cell carcinoma and complications during chemotherapy of hematologic malignancies [22–28]. Oral hygiene status is also crucial for human health, with poor oral hygiene linked to the onset of head and neck cancer [29]. Furthermore, good oral hygiene is related to the early improvement of inflammation after oral cancer and cardiac surgery [30, 31]. These studies suggest that the gut and oral microbiota play important roles in overall health and are associated with cancer. F. nucleatum is a species of interest in gut and oral microbiota research. It is a Gram-negative anaerobic rod bacterium that is specific to the human oral cavity and gastrointestinal tract. F. nucleatum, also known as periodontium, is prone to biofilm formation due to its high aggregation capacity, a feature that is of great importance in the context of cancer treatment [32–36]. Recent reports highlight the association between F. nucleatum and gastrointestinal cancer. The high prevalence of F. nucleatum in colorectal lesions is associated with a poor OS and increased recurrence rates [19, 37, 38]. Furthermore, a high abundance of F. nucleatum enhances chemotherapy resistance in colorectal cancer [39]. Recently, similar findings were reported in patients with esophageal squamous cell carcinoma, wherein the presence of F. nucleatum in the tumor tissue was associated with reduced patient survival and increased chemotherapy resistance [40, 41]. In colorectal cancer, the presence of F. nucleatum has been linked to resistance to immune checkpoint inhibitors [42]. However, much remains unknown about the effects of F. nucleatum on radiotherapy. This article will focus on Fusobacterium, an important bacterium in the gut and oral cavity. Specifically, we will summarize the latest findings on its impact on cancer treatment, with a particular emphasis on radiation therapy. In addition, findings on the impact of Fusobacterium in the field of esophageal cancer are also summarized. Moreover, the potential applications of these findings in cancer research will be discussed. General role of F. nucleatum F. nucleatum is a key component of the human oral and gastrointestinal microbiota that has significant roles beyond its association with periodontal disease, such as negatively affecting the healthy gut microbiome and being implicated in tumorigenesis and modulation of the tumor immune microenvironment. Recent findings suggest that this bacterium can alter the intestinal tumor environment to promote tumor growth, indicating its potential impact on gastrointestinal tract tumorigenesis [43]. Furthermore, the unique F. nucleatum adhesin flavin adenine dinucleotide A (FadA) facilitates its binding with cancer cells, resulting in the promotion of proliferation and metastasis. Additionally, F. nucleatum binds to E-cadherin on colorectal cancer cells and activates β-catenin signaling, thus facilitating cancer progression [44]. The ability of this bacterium to aggregate with other bacterial species, facilitated by cell surface proteins such as FadA and FomA, underscores its pivotal role in microbial community dynamics [32–34]. This feature is particularly significant in cancer cases, as aggregation of F. nucleatum with certain bacterial species is linked to disease progression, such as distant metastasis and lymph node invasion in colorectal cancer [35], whereas its interactions with oral epithelial cells (mediated by Toll-like receptors) directly impact tumor formation [36]. The aggregation ability of F. nucleatum may have implications for radiotherapy efficacy, a treatment modality that inflicts DNA damage in cancer cells [45]. The microbial community formed owing to this aggregation ability is speculated to increase resistance to radiation [46] by attracting neutrophils to tumor tissues and releasing cytokines that enhance resistance to radiotherapy, thus potentially reducing treatment effectiveness [47, 48]. Indeed, a high gene expression signature of neutrophils infiltrating tumors in patients with cervical cancer undergoing radiotherapy is associated with reduced survival rates [49]. This complex interplay between the aggressive behavior of F. nucleatum and its interaction with cancer cells underscores its multifaceted role in the human body, including influence on the microbial ecosystem and direct effects on cancer progression through mechanisms such as immune evasion and inflammation promotion (Fig. 1). Fusobacterium nucleatum binds to esophageal tumor cells via its surface adhesin, fibroblast activation protein-2 (Fap2), which targets glycan structures like galactose-N-acetyl galactosamine. This interaction enables the bacteria to colonize and persist within the tumor environment. It also triggers inflammatory responses through TLR4 on macrophages and other immune cells, leading to the production of cytokines such as interleukin (IL)-6 and IL-8, which in turn promote tumor growth. Additionally, the bacteria disrupt cancer cell control regulation by interacting with E-cadherin, thereby enhancing cell proliferation. F. nucleatum also compromises immune defense by inhibiting natural killer (NK) cell functions and facilitating tumor evasion. Additionally, it may bolster chemotherapy and radiotherapy resistance in cancer cells by altering autophagy and survival pathways, highlighting its critical role in tumor progression and therapeutic responses. Effect of F. Nucleatum on chemotherapy and immunotherapy Studies investigating the mechanisms by which F. nucleatum contributes to chemoresistance have provided important insights that could lead to the development of novel and effective cancer therapies. One study demonstrated that F. nucleatum can promote colorectal cancer resistance to chemotherapy by modulating autophagy, which is a crucial mechanism used by this bacterium to influence chemoresistance based on its interactions with cancer cells and the tumor microenvironment [50]. Additionally, the bacterium induces autophagy in colorectal cancer cells, a process that can degrade chemotherapeutic agents within the cells, thereby reducing their cytotoxic effects. Furthermore, F. nucleatum can alter the immune response within the tumor microenvironment, which plays a critical role in chemoresistance. In this regard, tumor cells were protected by F. nucleatum from the cytotoxic effects of chemotherapy via activation of the immune checkpoint inhibitor programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway, which suppresses the ability of the immune system to attack cancer cells [51, 52]. Additionally, this bacterium affects the expression of genes in cancer cells related to drug resistance. Another study revealed that infection with this bacterium in colorectal cancer cases led to increased expression of the drug-resistant gene multidrug resistance protein 1 through activation of the Toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 signaling pathway, thus enhancing the efflux of chemotherapeutic drugs from cancer cells and reducing their effectiveness [53]. In immunotherapy, succinic acid, a metabolite produced by F. nucleatum, has been shown to decrease the response of colorectal cancer to immunotherapy. Fecal F. nucleatum and serum succinate may be noninvasive biomarkers for predicting the treatment outcomes of immunotherapy. Additionally, the eradication of F. nucleatum with the antibiotic metronidazole may resensitize F. nucleatum-induced resistant tumors against anti-PD-1 antibodies in vivo [37]. In contrast, F. nucleatum has been shown to induce PD-L1 expression by activating stimulator of interferon genes signaling. This cascade of events was shown to enhance tumor sensitivity to anti-PD-1 antibodies [54]. This outcome, due to its potential to improve the treatment of cancer, should be studied in greater depth. In a study focusing on esophageal cancer, F. nucleatum was shown to modulate endogenous microtubule-associated protein light chain 3 (LC3) and autophagy-related protein 7 expression and induce chemotherapy resistance through autophagosome formation [55]. F. nucleatum has also been shown to induce the enrichment of immunosuppressive bone marrow-derived suppressor cells (i.e. via the activation of the NOD-like receptor protein 3 inflammasome) and also drive cisplatin resistance [56]. Furthermore, F. nucleatum has been shown to invade and survive in aging esophageal cancer cells, induce DNA damage and promote chemotherapy-induced secretion of senescence-associated secretory phenotype, thus culminating in chemotherapy resistance [57]. Regarding immunotherapy, F. nucleatum inhibits T-cell proliferation and cytokine secretion. Additionally, F. nucleatum-Dps binds to the promoter of the PD-L1 gene and activates transcription factor-3, which transcriptionally upregulates PD-L1 expression, causing treatment resistance [58]. These findings underscore the multifaceted mechanisms by which F. nucleatum contributes to chemotherapy and immunotherapy, from inducing autophagy and altering immune responses to affecting gene expression, which are related to drug resistance. Attaining a deeper understanding of these mechanisms is crucial for developing strategies to counteract the influence of this bacterium on chemotherapy efficacy and obtain more effective treatments for various types of cancer, particularly those in which F. nucleatum plays a significant role, such as colorectal cancer. Additional research in this area is expected to pave the way for the development of novel therapeutic approaches that target interactions between F. nucleatum and the tumor microenvironment to overcome chemoresistance (Fig. 1). Effect of F. nucleatum on radiation therapy The mechanisms underlying the impact of Fusobacterium on radiotherapy, unlike in the case of pharmacotherapy, have not been elucidated. Fusobacterium has been shown to be useful as a predictor of therapeutic response to radiotherapy. For example, the expression of Fusobacterium in tumor tissue was higher in nonresponders to chemoradiotherapy for colorectal cancer [59, 60]. However, the role of gut bacteria on radiotherapy remains unclear. In a mouse model of colorectal cancer, buccal F. nucleatum has been shown to migrate and aggregate into the lesion, contributing to reduced radiotherapy efficacy and poor prognosis; the administration of metronidazole has been shown to reverse this adverse effect. This solution suggests that oral and intestinal bacteria may be synergistically related to radiotherapy efficacy. Specifically, it has been suggested that radiotherapy resistance occurs by allowing Fusobacterium to migrate and settle at cancer loci, causing an increase in the conversion from LC3-I to LC3-II, which is involved in autophagy by lipopolysaccharide (LPS) [61]. We speculate that the activation of autophagy by Fusobacterium LPS may be as significant in radiotherapy resistance, as it is in chemotherapy resistance (Fig. 1). Fusobacterium has also been reported to be involved in radiation toxicity. For example, a correlation was found between oral Fusobacterium and oral mucositis in head and neck cancer patients treated with radiation therapy [62]. An association with xerostomia has also been found in patients with thyroid cancer [63]. Additionally, antimicrobial treatment with Fusobacterium has been shown to reduce radiation-induced intestinal damage in a mouse model of colorectal cancer [61]. Moreover, radiation itself has been shown to alter gut bacterial composition. Finally, Fusobacterium has been reported to be increased in the gut microbiota composition of gynecological cancer patients treated with pelvic radiation therapy [64]. In the context of esophageal cancer, there are few studies on the impact of F. nucleatum on the efficacy of radiotherapy. For example, there have been reports of high Fusobacterium abundance in the intestinal flora of patients with severe acute radiation-induced esophagitis; this outcome may be used as a potential therapeutic target in the reduction of radiation toxicity [65]. A high relative abundance of Lactobacillus nucleus has been demonstrated in the gut microbiota of patients who responded to chemoradiotherapy for esophageal cancer [66]. These results suggest that there are malignant (Fusobacterium) and benign (Lactobacillus) species that drive treatment resistance, highlighting the impact of the dysbiosis of bacterial flora in the context of cancer treatment. However, further studies are needed to clarify the relationship between F. nucleatum and radiotherapy resistance in esophageal cancer, but it remains plausible that autophagy is promoted by Fusobacterium LPS, as in the case of colorectal cancer. It is also plausible that the high aggregation ability of Fusobacterium (i.e. as driven by cell surface proteins such as FadA and FomA) may suppress immune responses by forming biofilms, thereby promoting radiotherapy resistance. Bacteriological interventions to improve radiotherapy Gut microbiota (including F. nucleatum) can modulate the response of the body to radiation, potentially affecting therapeutic outcomes. For example, results highlighting the importance of the gut microbiome in mediating responses to cancer treatment suggest that manipulation of the microbiome can enhance the efficacy of radiation therapy [53]. Another study focusing on the broader implications of the role of the gut microbiome in modulating responses to radiation therapy in patients with cancer indicates that specific components of the microbiota (including potentially pathogenic bacteria such as F. nucleatum) can influence the outcomes of radiation therapy by altering the host immune response and possibly affecting mechanisms within tumor cells related to the repair of radiation-induced damage [67]. Furthermore, the presence of specific bacterial species in the gut is associated with variations in radiation-induced gastrointestinal syndrome severity, thus highlighting the role of the gut microbiome in the modulation of radiation toxicity and efficacy. Kumagai et al. [68] highlighted the potential of microbiome-based interventions to enhance the outcomes of radiation therapy. Thus, it may be possible to manipulate the composition of the gut microbiota to improve the efficacy of radiation therapy while reducing its side effects. To achieve such outcomes, the following solutions across the following variables could be implemented: probiotics, prebiotics, postbiotics, fecal transplants and antibiotics targeting specific bacterial species, or dietary modifications. The consumption of alcohol and smoking has also been reported to adversely affect the composition of the gut microbiota; thus, their limitation is a worthwhile effort to prevent microbiome dysbiosis [69–71]. Periodontal treatment also seems to be an important approach, as results have been reported that periodontal treatment decreases F. nucleatum in stools in patients with colorectal tumors; this translates to the possibility that stool bacteria correlate with the progression of tumor atypia [72]. It should also be noted, as mentioned earlier, that radiotherapy itself has been reported to increase F. bacterium, potentially having a negative impact on treatment and altering the composition of gut microbiota [64] (Fig. 2). In radiotherapy, a well-balanced gut microbiota composition, specifically improved dysbiosis, affects the efficacy of radiation therapy and the reduction of radiation toxicity. This is attributed to enhanced host immune response and reduced repair of radiation-induced damage in the tumor, as well as improved bacterial truncation. Radiotherapy itself has a negative effect on the favorable gut microbiota composition. Potential approaches to achieve this improvement include probiotics, prebiotics, postbiotics, fecal microbiota transplantation, targeted antibiotic use against specific bacteria, dietary modifications, reduction of alcohol consumption and smoking and periodontal treatment. A comprehensive understanding of the bacterial flora and its relationship to ecology and cancer could be used to combat bacteria-driven treatment resistance, improve treatment outcomes and reduce side effects. This emerging field holds promise for the development of integrated cancer therapies that directly target the tumor and modulate the microbiome to support therapeutic efficacy, ultimately improving the effectiveness of radiation therapy for cancer. Clinical significance and future research perspectives The accumulating evidence for the role of F. nucleatum in the treatment of cancer, particularly in relation to esophageal malignancies, underscores the urgent need for more comprehensive studies into these dynamics. Although the role of F. nucleatum in colorectal cancer has received considerable attention, its involvement in esophageal cancer remains largely unresolved. One of the features of F. nucleatum that have been linked to a lowered efficacy of various cancer treatments is its ability to promote aggregation, which may have a significant impact on microbial community dynamics and biofilm formation. This feature may also shape the tumor microenvironment by forming niche spaces that protect tumor cells from therapeutic interventions and immune responses. Overall, these trends underscore the importance of further study of these complex interactions for the advancement of cancer therapy [47, 73–76]. Currently, we have successfully isolated F. nucleatum from esophageal cancer tissue from esophageal cancer patients who underwent radiation therapy and chemotherapy. To our knowledge, F. nucleatum from esophageal cancer tissues has not been isolated. These isolates may host F. nucleatum populations unique to those of cancer-free people. To gain more insight into F. nucleatum, we are currently investigating this bacteria across various resolutions (i.e. even at subspecies level). Additionally, we are in the process of examining the relationship between the subspecies in oral flora and esophageal cancer tissue and the differences in aggregation ability of various subspecies of this genus. F. nucleatum plays an important role in the oral and gastrointestinal microbiome and is composed of five known subspecies: nucleatum, polymorphum, vincenti, fusiforme and animalis. These subspecies each have unique biological characteristics and may have individually different effects on associated diseases [77]. Furthermore, the diversity among these subspecies reflects the adaptability and ecological diversity of F. nucleatum, which may be involved in the pathogenesis of various diseases, including cancer. For example, F. nucleatum subsp. animalis has been shown to promote inflammation in the tumor microenvironment of colorectal cancer, specifically by increasing the expression of inflammatory cytokines and activating monocytes [78]. Inflammation is an important factor in cancer progression because it yields an environment that is optimal for the proliferation of cancer cells. In addition, F. nucleatum subsp. polymorphum is known for its transgenic capacity and rich repertoire of unique open reading frames, suggesting a high degree of interaction with other microbes within the host [79]. This subspecies may also influence a variety of biological functions, from microbial community dynamics to interactions with the host immune system. Such abilities highlight the potential for certain F. nucleatum subspecies to influence disease processes, such as modulating host immune responses and promoting microbial dysbiosis, which can influence cancer development and progression. One study delved into the implications of F. nucleatum interactions within the host, with a particular focus on their association with inflammatory processes that may predispose individuals to cancer [80, 81]. We found that virulence factors of F. nucleatum, such as FadA, which vary among subspecies, may mediate adhesion and invasion of host epithelial cells and trigger inflammatory pathways known to be involved in carcinogenesis. Additionally, valuable insights into the role of F. nucleatum in oral and gastrointestinal cancers have been provided. For example, it has been shown that different subspecies of this bacterium preferentially colonize tumor sites, suggesting a complex interplay between subspecies diversity and the tumor microenvironment [82]. Such colony dynamics have been linked to the modulation of the immune response, possibly affecting tumor growth and progression, highlighting the possibility of specific F. nucleatum subspecies potentially shaping (directly or indirectly) cancer etiology. Our future work will entail finer-scale investigations into the relationship between F. nucleatum and its various subspecies. Such studies will be conducted on the basis of F. nucleatum isolates obtained from esophageal cancer tissues. We will then explore the role of F. nucleatum in esophageal cancer in the etiology of esophageal cancer and its resistance to radiation therapy and chemotherapy. Such studies will be crucial in elucidating novel mechanisms by which F. nucleatum influences biofilm formation, cancer development and even resistance to therapy. The development of subspecies-specific biomarkers is a promising avenue to significantly impact diagnostic and therapeutic strategies for gastrointestinal cancers, while simultaneously facilitating the development of more accurate microbiologically informed approaches to address cancer progression. The role of F. nucleatum in modulating immune responses and influencing disease progression, as observed in studies of colorectal and pancreatic cancers, suggests that similar mechanisms may occur in esophageal cancer [47]. Biofilm formation has been suggested to confer oxygen tolerance and invasiveness to F. nucleatum, increasing the spread of infection and resistance to treatment, highlighting the need for targeted studies focused on controlling or eradicating this organism without upsetting the host’s immune balance [73–75]. CONCLUSION F. nucleatum, a component of the oral microflora and one of the periodontopathic bacteria, is one of the most notable bacterial species in cancer therapy, and the current findings in cancer therapy, including radiotherapy, are summarized. Furthermore, future prospects in esophageal cancer therapy are discussed. Continued research on the role of F. nucleatum is essential to advance cancer treatment and improve patient care. CONFLICT OF INTEREST The authors declare no conflict of interest. FUNDING None. Contributor Information Manato Ohsawa, Department of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Hiromi Nishi, Department of General Dentistry, Hiroshima University Hospital, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Manabu Emi, Department of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Toru Yoshikawa, Department of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Yoichi Hamai, Department of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Yuta Ibuki, Department of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Tomoaki Kurokawa, Department of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Ryosuke Hirohata, Department of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Nao Kitasaki, Department of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Miki Kawada-Matsuo, Department of Bacteriology, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Hitoshi Komatsuzawa, Department of Bacteriology, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Hiroyuki Kawaguchi, Department of General Dentistry, Hiroshima University Hospital, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. Morihito Okada, Department of Surgical Oncology, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan. REFERENCES